

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

NU-DHL-1

RRID:CVCL_1876

Type: Cell Line

Proper Citation

RRID:CVCL_1876

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1876

Proper Citation: RRID:CVCL_1876

Description: Cell line NU-DHL-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma

Defining Citation: [PMID:2581902](#), [PMID:8547074](#), [PMID:9787181](#), [PMID:19278952](#), [PMID:22460905](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NU-DHL-1

Synonyms: Nu-DHL-1, NUDHL1, NuDHL 1

Cross References: ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473488, BioSample:SAMN10988456, cancercellines:CVCL_1876, Cell_Model_Passport:SIDM01780, ChEMBL-Cells:ChEMBL4523521, ChEMBL-Targets:ChEMBL4523552, Cosmic:850208, Cosmic:1629931, Cosmic:2361378, DepMap:ACH-000388, DSMZ:ACC-583, DSMZCellDive:ACC-583, GEO:GSM380139, GEO:GSM380140, GEO:GSM887459,

GEO:GSM888539, GEO:GSM1035330, GEO:GSM1374775, IARC_TP53:28228, LiGeA:CCLE_037, Pharmacodb:NUDHL1_1170_2019, Progenetix:CVCL_1876, PubChem_Cell_line:CVCL_1876, Wikidata:Q54931148

ID: CVCL_1876

Record Creation Time: 20220427T221349+0000

Record Last Update: 20260904T015318+0000

Ratings and Alerts

No rating or validation information has been found for NU-DHL-1.

No alerts have been found for NU-DHL-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Peck B, et al. (2021) 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research, 81(4), 847.